Abstract
Introduction

37
A split virion (SV) vaccine is widely used for current seasonal influenza vaccination in humans 38 and is administered intramuscularly [1] . However, the efficacy of SV is highly controversial since 39 the current vaccination method would not be the best combination of antigen and administration 40 route to induce antibody responses [2] . An inactivated whole virus particle (WVP) vaccine has 41 been reported to induce stronger antibody responses than an SV vaccine in animal studies [3] [4] [5] [6] .
42
Although WVP vaccines were discontinued in the 1990s due to a problem with their reactogenicity
43
[7], WVP already has been an attractive formulation as a pandemic vaccine because a WVP vaccine 44 is more immunogenic than an SV vaccine in individuals who have not been exposed to vaccine 45 antigens before [8] . Thus, WVP is the recommended formulation for pandemic vaccines against 46 H5N1 influenza viruses in Japan, and majority of the population in Japan is expected to be 47 ], generated 79 from two nonpathogenic avian influenza viruses, which is antigenically similar to HK483 (H5N1) 80 [23, 24] , were used in the present study. All viruses were propagated in 10-day-old embryonated 81 chicken eggs at 35°C for 36-48 h, and the infectious allantoic fluids were collected. Virus stocks 82 were stored at −80°C until use.
Materials and Methods
76
Viruses and cells
83
MDCK cells were grown in Minimum Essential Medium (MEM) (Nissui Pharmaceutical, 84 Tokyo, Japan) supplemented with 10% calf serum. The cells were used for plaque assays and 85 serum neutralization tests. with the study of Kida et al. [25] . The total protein concentration was measured using the BCA
92
Protein Assay Kit (Thermo Fisher Scientific, Massachusetts, USA). SV of each strain was prepared 93 by the ether split method [26] . In brief, purified viruses were disrupted with 0.05% Tween 80 and an equal volume of diethyl ether for 30 min at room temperature. The water phase was collected 95 after centrifugation for 30 min at 3,500 g. The ether dissolved in the water phase was removed by 96 ultracentrifugation. The abundance of hemagglutinin (HA) protein was calculated from the 97 intensity ratio of HA protein to total protein by sodium dodecyl sulfate-polyacrylamide gel 98 electrophoresis (SDS-PAGE). The purified viruses were inactivated with 0.2%-0.3% formalin at 99 4°C for 7-14 days, and the formalin was removed by ultracentrifugation. 
Results
174
Dissolving kinetics of a novel developed MN in mouse skin
175
The MN patches were designed for the efficient delivery of antigens into mouse skin (Fig. 1A ).
176
Evans blue was encapsulated in the MN patches as a marker instead of vaccine antigens to facilitate 177 imaging (Fig. 1B ). All the components had dissolved in the skin after 5 min ( (Table 1) .
193
Protection of mice vaccinated by MN against challenge with PR8 (H1N1)
194
Four weeks after prime immunization, the mice were challenged with 10 MLD50 of PR8 In particular, the survival rate of mice vaccinated by MN with 0.01 µg of WVP was 100% without 228 body weight loss (Fig. 3A, D) . In contrast, the survival rates were 0% in the groups of mice 229 subcutaneously vaccinated with 0.01 µg of WVP or SV (Fig. 3B) <20, 20, 20, 20, 40, 80, 80, 160 5.83 ± 0.63* 0.05 20, 40, 80, 160, 160, 160, 160, 160, 320, 320, 640, 1,280 1.81 ± 0.79* 0.25 80, 160, 160, 160, 160, 160, 320, 320, 320, 320, 640, 640 0.00 ± 0.00* SV 0.01 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 7.68 ± 0.14 0.05 20, 40, 40, 40, 40, 40, 40, 40, 80, 80, 80, 160 6.91 ± 0.40 0.25 40, 80, 80, 160, 160, 160, 160, 160, 320, 320, 320, 320 5.14 ± 0.54* subcutaneous injection WVP 0.01 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 7.60 ± 0.15 0.05 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, 80 7.42 ± 0.09 0.25 <20, <20, <20, <20, <20, 20, 40, 40, 40, 40, 80, 160 6.63 ± 0.34** SV 0.01 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 8.15 ± 0.08 0.05 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 7.89 ± 0.06 0.25 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, 20, 80 7.63 ± 0.16 PBS MN --<20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 7.89 ± 0.10 subcutaneous injection --<20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 8.07 ± 0.19
Each of vaccine was administrated by microneedle (MN) or subcutaneously into 12 mice. Mice were challenged with 10 MLD 50 (10 4.5 PFU) of PR8 (H1N1).
"-" indicates that no vaccine is included. * P < 0.05, vs. virus titers in PBS group vaccinated transdermally. ** P < 0.05, vs. virus titers in PBS group vaccinated subcutaneously. SV, split virion; WVP, whole virus particle Vac-3 (H5N1) MN WVP 0.01 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.05 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.25 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, 20 ND ES 0.01 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.05 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.25 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND subcutaneous injection WVP 0.01 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.05 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.25 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND ES 0.01 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.05 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND 0.25 <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND PBS MN --<20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND subcutaneous injection --<20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 ND Two injections Vac-3 (H5N1)×2 MN WVP 0.01×2 <20, 20, 20, 20, 20, 40, 80, 160, 160, 160, 320, 320 5.48 ± 0.23 0.05×2 <20, <20, <20, 20, 80, 80, 160, 320, 320, 320, 320, 640 3.67 ± 0.73* 0.25×2 80, 80, 160, 320, 320, 320, 640, 640, 640, 640, 1,280, 2,560 0.82 ± 0.48* SV 0.01×2 <20, <20, <20, <20, <20, <20, <20, <20, 20, 40, 40, 80 5.67 ± 0.12 0.05×2 20, 20, 20, 40, 40, 40, 40, 40 80, 160, 160, 320 4.16 ± 0.43* 0.25×2 <20, 80, 80, 80, 80, 160, 160, 320, 320, 1,280, 1,280, 1,280 1.20 ± 0.70* subcutaneous injection WVP 0.01×2 <20, <20, <20, <20, <20, <20, <20, <20, <20, 20, 20, 20 6.26 ± 0.09 0.05×2 <20, <20, <20, <20, <20, <20, <20, <20, <20, 20, 80, 80 5.49 ± 0.25 0.25×2 <20, <20, <20, <20, <20, 80, 80, 80, 80, 160, 320, 320 4.19 ± 1.22 SV 0.01×2 <20, <20, <20, <20, <20, <20, <20, 20, 20, 20, 20, 20 6,20 ± 0.19 0.05×2 <20, <20, <20, <20, <20, <20, 20, 20, 20, 20, 20, 80 5.98 ± 0.08 0.25×2 <20, <20, <20, <20, <20, 40, 40, 160, 320, 320, 320 5.27 ± 0.31 PBS×2 MN --<20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 5.78 ± 0.27 subcutaneous injection --<20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20, <20 5.74 ± 0.20 Each of vaccine was administrated by MN or subcutaneously into 12 mice. Mice were challenged with 30 MLD 50 (10 2.3 EID 50 ) of HK483 (H5N1).
"-" indicates no vaccine is included. * P < 0.05, vs. virus titers in PBS group vaccinated transdermally. ** P < 0.05, vs. virus titers in PBS group vaccinated subcutaneously. ND: Not done SV, split virion; WVP, whole virus particle Table 2 . Neutralizing antibody titers of mice injected with the vaccine and virus titers in the lungs after challenge against HK483 (H5N1)
